Nearly 3 in 4 older adults said they would likely or definitely get a vaccine to prevent against high risk of dementia.

Use of Probenecid as an Anti-Virulence Agent Against Listeria monocytogenes is a drug-repurposing technology that uses the FDA-approved drug probenecid to reduce the disease-causing ability of Listeria monocytogenes without significantly affecting bacterial growth under tested laboratory conditions. Rather than killing the bacteria, the approach targets virulence mechanisms, including hemolytic activity and intracellular persistence, potentially reducing infection severity while limiting the selective pressure associated with traditional antibiotics. The technology may be developed as a standalone or adjunctive therapy for listeriosis in human and veterinary settings. The patent-pending technology is at TRL 3 (early proof of concept) and available for licensing.

Intestinal apoM Inhibition as a Specific Approach to Reduce Plasma Chylomicron and Triglyceride Levels is a novel therapeutic strategy that targets apolipoprotein M (apoM) in the intestine to reduce the production of chylomicrons, a highly atherogenic class of lipid particles linked to cardiovascular disease. By acting at the source of post-meal lipid absorption, the technology lowers plasma triglyceride levels through a mechanism not addressed by current lipid-lowering therapies. Its intestine-specific approach may minimize systemic side effects while offering new treatment options for cardiovascular disease, metabolic syndrome, and hypertriglyceridemia. The patent-pending technology is at TRL 3, with proof of concept demonstrated in preclinical models, and is available for licensing.

A HNF4α-caGR Fusion Transcription Factor as a Potential Treatment for Inflammatory Liver Diseases and Liver Cancer is a novel protein-based therapeutic that combines hepatocyte nuclear factor 4α (HNF4α) and a constitutively active glucocorticoid receptor (caGR) to restore critical liver functions and reduce inflammation. By simultaneously activating two key regulatory pathways involved in liver cell differentiation, metabolism, and anti-inflammatory responses, the technology is designed to overcome resistance mechanisms that limit current treatments. Its selective, liver-focused approach may reduce the systemic side effects associated with conventional glucocorticoid therapies. Potential applications include inflammatory liver diseases, liver cancer, and other disorders involving transcriptional dysregulation. The technology is patent pending and available for licensing.